Federal contract award
HHSO100201600030C
IGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $1.4B |
| Current contract value | $1.4B |
| Potential contract value / ceiling | $1.5B |
| Start date | Sep 30, 2016 |
| Current end date | Sep 29, 2026 |
| Potential end date | Sep 29, 2026 |
| Latest award activity | Aug 18, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 22 of 22 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 18, 2026 | P00021 | $24.0M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Aug 29, 2025 | P00020 | $30.0M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Apr 4, 2025 | P00019 | $0 | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Dec 12, 2024 | P00018 | $50.0M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Jun 26, 2024 | P00017 | $30.0M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Nov 21, 2023 | P00016 | $75.0M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Oct 6, 2023 | P00015 | $0 | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Jun 16, 2023 | P00014 | $75.0M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Mar 30, 2023 | P00013 | $4.5M | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Dec 2, 2021 | P00012 | $0 | EO14042 EMERGENT AV7909 ANTHRAX VACCINE |
| Sep 30, 2021 | P00011 | $398.6M | EMERGENT AV7909 ANTHRAX VACCINE |
| Jun 10, 2021 | P00010 | $0 | EMERGENT AV7909 ANTHRAX VACCINE |
| Apr 22, 2021 | P00009 | $0 | EMERGENT AV7909 ANTHRAX VACCINE |
| Mar 22, 2021 | P00008 | $0 | EMERGENT AV7909 ANTHRAX VACCINE |
| Nov 19, 2020 | P00007 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO MODIFY ARTICLE G.3 KEY PERSONNEL. |
| Jul 13, 2020 | P00006 | $258.0M | THE PURPOSE OF THIS MODIFICATION IS TO MODIFY ARTICLES B.3 OPTION PRICES, B.5 ADVANCE UNDERSTANDINGS, C.1 STATEMENT OF WORK AND SECTION J ? LIST OF ATTACHMENTS. |
| Apr 10, 2020 | P00005 | $0 | UPDATE LANGUAGE IN SECTION B.3 OPTION PRICES, B.5 ADVANCE UNDERSTANDINGS, F.3 DELIVERIES, G.1 CONTRACTING OFFICER, AND G.4 INVOICE SUBMISSION |
| Mar 3, 2020 | P00004 | $0 | UPDATE LANGUAGE IN SECTION B.5 ADVANCE UNDERSTANDINGS AND G.3 KEY PERSONNEL |
| Jul 30, 2019 | P00003 | $261.0M | OPTION FUNDING TO SUPPORT PROCUREMENT OF AV7909 |
| Aug 29, 2018 | 2 | $5.0M | IGF::OT:IGF |
| Mar 16, 2017 | 1 | $0 | IGF::OT:IGF |
| Sep 30, 2016 | 0 | $198.7M | IGF::OT::IGF |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.